Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON30135
NL-OMON30135
Not yet recruiting
Not Applicable

Cerebrospinal fluid metabolites as marker for the severity of progressive post-hemorrhagic ventricular dilatation in preterm infants - Cerebrospinal fluid metabolites in post-hemorrhagic ventricular dilatation

niversitair Medisch Centrum Sint Radboud0 sites125 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
125
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • •Preterm infants (gestational age \< 34 weeks) with intraventricular hemorrhage grade III and progressive post\-hemorrhagic ventricular dilatation

Exclusion Criteria

  • •congenital cerebral malformation
  • •cerebral parenchymal hemorrhage/infarction
  • •periventricular leucomalacia
  • •PHVD already present at birth
  • •infection of the CNS
  • •metabolic disorder

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
The value of biomarkers in cerebrospinal fluid in acute spinal cord injury as predictor of outcome.spinal cord injurytraumatic myelopathy10041543
NL-OMON34689niversitair Medisch Centrum Sint Radboud30
Completed
Not Applicable
Plasma and cerebrospinal fluid concentrations treated with daily dose and high dose weekly erlotinib in non-small cell lung cancer patients with central nervous system metastasescentral nervous system metastases of non-small cell lung cancer with active EGFR mutations treated with daily dosing erlotinib
JPRN-UMIN000004703Osaka City University10
Completed
Phase 4
Comparative plasma and cerebrospinal fluid pharmacokinetics of paracetamol following intravenous and oral administratio
ACTRN12615000322538Royal Melbourne Hospital21
Completed
Not Applicable
Research on measurements of brain metabolites including glucose using 7T-MRIHealthy volunteers
JPRN-UMIN000029047Human Brain Research Center, Graduate School of Medicine, Kyoto University40
Recruiting
Not Applicable
Identification of a CSF- and blood biomarker fingerprint differentiating between highly active and moderate/mild forms of multiple sclerosis (MS)G35Multiple sclerosis
DRKS00015761Klinikum der Johann Wolfgang Goethe-UniversitätZentrum der Neurologie und Neurochirurgie200